findmyKOL

Russell Schilder, MD

Enriched profile

Emeritus Faculty, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University · Thomas Jefferson University

ORCIDNone on fileNPI
Region🇺🇸 Philadelphia, PA · Northeast · United StatesSpecialtyMedical OncologyFocusOvarian / Gynecologic Cancer+14
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2020Online presenceNone verifiedPayments2021–2025NIH funding1992–2024Why? →

Russell Schilder is Emeritus Faculty, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University at Thomas Jefferson University. ClinicalTrials.gov lists 15 registered studies with this person as an investigator.

Data verified 17 Aug 2026

Overview

Updated 2 Sept 2026

Russell J. Schilder, M.D., is Emeritus Faculty, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University. The public record shows 209 publications with 11,810 citations (h-index 52), centered on Ovarian / Gynecologic Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 11 companies, 3 NIH-funded awards (1992–2024).

  • Top research focus: Ovarian / Gynecologic Cancer
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 11 companies

Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer8 trialsFallopian Tube Neoplasms2 trialsUterine Cervical Neoplasms2 trialsCarcinoma, Ovarian Epithelial2 trialsLung Cancer (NSCLC/SCLC)1 trialLymphoma1 trialEndometrial Neoplasms1 trialMultiple Myeloma1 trialCarcinoma, Squamous Cell1 trialCysts1 trialCarcinoma, Endometrioid1 trialCystadenocarcinoma, Serous1 trialCystadenocarcinoma, Mucinous1 trialCystadenocarcinoma1 trialPeritoneal Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Ovarian / Gynecologic CancerCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsUterine Cervical NeoplasmsCarcinoma, EndometrioidCarcinoma, Squamous CellCystadenocarcinomaCystadenocarcinoma, MucinousCystadenocarcinoma, SerousCystsEndometrial NeoplasmsLung Cancer (NSCLC/SCLC)LymphomaMultiple MyelomaPeritoneal Neoplasms

Drugs & molecules

across trials, industry payments and publications
Elaheregeneric · Mirvetuximab soravtansineClinical trialsIndustry payments1PublicationsLibtayogeneric · CemiplimabClinical trialsIndustry payments1PublicationsLynparzageneric · OlaparibClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Incyte CorporationClinical trialsIndustry payments46Gynecologic Oncology GroupClinical trials6Industry paymentsEisai Inc.Clinical trialsIndustry payments5

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
52h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials
11companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
3NIH grants · 1992–2024

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 2 Sept 2026

Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 2 Sept 2026

11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    100%
    Opioid Agonist100%
    Morphine Sulfate Er100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 2 Sept 2026

3 NIH research awards on record, funded 19922024 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 2 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    contexttherapeutics.com/team-bios/karenandreas-3alcy-yt3a9

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →contexttherapeutics.com
  • Other

    onclive.com/authors/russell-j-schilder-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 2 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    University of Miami School of Medicine

    1983
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jefferson.edu
  • Board Certified

    Medical Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jefferson.edu
  • Board Certified

    Hematology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jefferson.edu
  • Board Certified

    Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jefferson.edu
  • M.S.

    University of Miami

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →contexttherapeutics.com

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.